Grant: CIHR Fellowship
University of Ottawa
$75,000.00
Role of the RNA-binding protein Staufen1 in Myotonic Dystrophy type 1
FY 2009-10
Summary
Myotonic Dystrophy type 1 (DM1) affects 1/8000 individuals worldwide and 1/500 in Saguenay area in Quebec, Canada. The disease affects muscles, which become weak (dystrophy), painful and have trouble to relax following contraction (myotonia). It also affects other organs such as the heart (cardiac defects), eyes (cataract), the nervous system (cognitive impairments), and the endocrine system (insulin resistance). DM1 is a genetic disorder characterized by an autosomal dominant transmission. The genetic abnormality is located on chromosome 19, and is caused by a pathological expansion of a small DNA sequence (CTG trinucleotide) in the DMPK gene (for Dystrophia Myotonica Protein Kinase) which affects the normal function of the cell. The expanded RNA which is expressed by this gene is confined into the nucleus of the cell were it aggregates. The presence of these aggregates become toxic to the cell because it sequesters proteins called RNA-binding proteins which are normally destined to regulate important cell functions. In particular, it induces perturbations in the formation (transcription) and maturation (splicing) of other RNAs produced by the cell.
Our goal is to better understand the mechanisms resulting from the accumulation of the expanded RNA in the nucleus of the pathological cells. In particular, we attempt to identify RNA-binding proteins which interact with the expanded RNA and become misregulated in these cells. We have identified a RNA-binding protein called Staufen1 which is able to interact with the DMPK RNA. Our work shows that the regulation of Staufen1 can affect the expanded RNA accumulation in the nucleus and improve the splicing perturbations observed in the disease. We now propose to pursue our efforts in the elucidation of the specific role of Staufen1 in DM1. It is hoped that the comprehension of these mechanisms will lead to a deeper understanding of the DM1 disease, and in turn uncover new therapeutic targets.
Department
Program
CIHR Fellowship
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
203463
Name
Ravel-Chapuis Aymeric
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Role of the RNA-binding protein Staufen1 in Myotonic Dystrophy type 1
Programtype2
Fellowship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$75,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Gene Expression; Mouse Model Of Human Disease; Myotonic Dystrophy; Post-Transcriptional Regulation; Rna Gain Of Function; Rna Regulation; Rna Splicing; Rna-Binding Protein; Skeletal Muscle; Staufen1 Protein
Abstract
Myotonic Dystrophy type 1 (DM1) affects 1/8000 individuals worldwide and 1/500 in Saguenay area in Quebec, Canada. The disease affects muscles, which become weak (dystrophy), painful and have trouble to relax following contraction (myotonia). It also affects other organs such as the heart (cardiac defects), eyes (cataract), the nervous system (cognitive impairments), and the endocrine system (insulin resistance). DM1 is a genetic disorder characterized by an autosomal dominant transmission. The genetic abnormality is located on chromosome 19, and is caused by a pathological expansion of a small DNA sequence (CTG trinucleotide) in the DMPK gene (for Dystrophia Myotonica Protein Kinase) which affects the normal function of the cell. The expanded RNA which is expressed by this gene is confined into the nucleus of the cell were it aggregates. The presence of these aggregates become toxic to the cell because it sequesters proteins called RNA-binding proteins which are normally destined to regulate important cell functions. In particular, it induces perturbations in the formation (transcription) and maturation (splicing) of other RNAs produced by the cell.
Our goal is to better understand the mechanisms resulting from the accumulation of the expanded RNA in the nucleus of the pathological cells. In particular, we attempt to identify RNA-binding proteins which interact with the expanded RNA and become misregulated in these cells. We have identified a RNA-binding protein called Staufen1 which is able to interact with the DMPK RNA. Our work shows that the regulation of Staufen1 can affect the expanded RNA accumulation in the nucleus and improve the splicing perturbations observed in the disease. We now propose to pursue our efforts in the elucidation of the specific role of Staufen1 in DM1. It is hoped that the comprehension of these mechanisms will lead to a deeper understanding of the DM1 disease, and in turn uncover new therapeutic targets.
Competitiondate
201002
Approvedterm2
1 yr 8 mths
Pinamesdelim
Ravel-Chapuis, Aymeric
Approvedterm
1 an 8 mois
Cihrcontribution2
~ $75,000~ $0~